| This week's sponsor is Dell EMC. | | | [Webinar] Is Your Life Science Data "F-A-I-R"?
Tuesday, February 13 | 2pm ET / 11am PT
Is Your Life Science Data "F-A-I-R"? Join DataFrameworks & Dell EMC in this webinar to discover a new approach to create scientific data that is findable, accessible, interoperable, and reusable. Register now! |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Tuesday, February 6, 2018 One year after officials in Greece began investigating Novartis on bribery allegations in a probe that quickly assumed soap-opera proportions, the country’s leaders are ratcheting up the pressure—implicating 10 former ministers and ordering one of the Swiss pharma giant’s local managers not to leave the country pending prosecution. |
|
|
Top Stories Of The Week Wednesday, February 7, 2018 Sanofi has dropped an anticancer antibody-drug conjugate it licensed from ImmunoGen. The French pharma gained full control of the anti-LAMP1 drug as part of a recent deal but has now removed the asset from its pipeline. Monday, February 5, 2018 Bristol-Myers Squibb finally got its win in first-line lung cancer—and it’s a success that not only helps confirm one immunotherapy combo approach that has been in doubt, but puts forward a diagnostic biomarker that could apply to other cancer types. Monday, February 5, 2018 Nektar Therapeutics could join the growing list of biotechs opting for a takeover, according to a Bloomberg report that it is exploring strategic options for the business. Monday, February 5, 2018 After ushering Juno Therapeutics through early fundraising, an IPO, clinical setbacks and more, CEO Hans Bishop is set to take home up to $287 million when the CAR-T player seals its buyout with Celgene. Wednesday, February 7, 2018 The FDA has approved Empatica’s seizure-detecting wearable for use by epilepsy patients. Empatica picked up the 510(k) clearance for Embrace after the device detected every seizure in a 135-patient clinical trial. Tuesday, February 6, 2018 Despite new challenges in shingles, Merck's vaccine business kept churning in 2017, generating sales of $6.5 billion—an increase of 4.8%. Monday, February 5, 2018 About half of all dementias, including Alzheimer's, start when tiny blood vessels in the brain malfunction, allowing toxic substances to flood the brain and disrupt communications. A University of Southern California team has discovered what starts that process. Tuesday, February 6, 2018 Construction of German CDMO Vetter’s new sterile injectables manufacturing facility—part of its $320 million plan to invest in a U.S. site in the Chicago area—appears to be getting pushed back until 2022. Monday, February 5, 2018 Charles River Laboratories has strengthened its high-throughput screening capabilities by gaining access to technologies available at AstraZeneca’s Centre for Lead Discovery in Cambridge, U.K. Resources Presented by: SDC and Stiris Research What do you do when timelines are missed, data is dirty, and everyone is pointing fingers? Watch this webinar to learn how to prevent, identify, and implement a successful clinical trial rescue. Presented by: Patheon Download Patheon’s whitepaper to discover two main areas where a drug developer can face significant obstacles during biologics development and how by evaluating these capabilities, it can answer the critical question of whether its in-house strategy is ready for these uncertainties. Sponsored by: Veeva Systems Expanding into new markets places a spotlight on inefficient processes. Sponsored by: Veeva Systems Regulatory leaders share challenges and best practices from a lack of standardization, manual processes, and fragmented systems. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. |
